Global Severe Acute Respiratory-Syndrome Treatment Market Size and Forecast 2024-2033 | Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG

Overview and Scope
Severe acute respiratory syndrome (SARS) refers to a serious form of pneumonia caused by an airborne virus that can spread through tiny droplets of saliva. It is previously unrecognized virus from the Coronaviridae family, the SARS-associated COVID-19 (SARS-CoV). Severe acute respiratory syndrome (SARS) treatment involves the medical interventions and supportive measures implemented to manage the symptoms and complications of the viral respiratory illness.

Sizing and Forecast
The severe acute respiratory-syndrome treatment market size has grown rapidly in recent years. It will grow from $2.99 billion in 2023 to $3.45 billion in 2024 at a compound annual growth rate (CAGR) of 15.3%.  The  growth in the historic period can be attributed to global outbreak response, antiviral drug development, vaccine development, public health preparedness.

The severe acute respiratory-syndrome treatment market size is expected to see rapid growth in the next few years. It will grow to $6.12 billion in 2028 at a compound annual growth rate (CAGR) of 15.4%.  The growth in the forecast period can be attributed to broad-spectrum antivirals, emerging therapeutics, vaccine advancements, pandemic preparedness. Major trends in the forecast period include rna-targeted therapies, ai in drug discovery, global collaborations, public health education.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/severe-acute-respiratory-syndrome-treatment-global-market-report

Segmentation & Regional Insights
The severe acute respiratory-syndrome treatment market covered in this report is segmented –

1) By Drug Class: Antibiotics; Antiviral; Corticosteroids; Monoclonal Antibodies; Other Drug Classes
2) By Route Of Administration: Oral; Intravenous
3) By Indication: Severe Acute Respiratory Syndrome COVID-19 (SARS-CoV); Severe Acute Respiratory Syndrome COVID-19 2 (SARS‑CoV‑2)
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Other Distribution Channels

North America was the largest region in the severe acute respiratory syndrome treatment market in 2023. Western Europe is expected to be the fastest-growing region in the forecast period. The regions covered in severe acute respiratory syndrome treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=13027&type=smp

Major Driver Impacting Market Growth

The growing incidence of respiratory diseases is expected to propel the growth of the severe acute respiratory syndrome treatment market going forward. Respiratory diseases refer to a group of medical conditions that affect the respiratory system responsible for breathing and the exchange of gases between the body and the external environment. Severe acute respiratory syndrome treatment is used in respiratory diseases to alleviate symptoms, prevent respiratory failure, reduce inflammation and maintain oxygen levels. For instance, in June 2023, according to reports shared by the Australian Institute of Health and Welfare, an Australia-based national agency, there was a rise in respiratory disease-related deaths from 43,031 in 2020 to 46,551 in 2021 in Australia. Therefore, the growing incidence of respiratory diseases is driving the growth of the severe acute respiratory syndrome treatment market.

Key Industry Players

Major players in the severe acute respiratory-syndrome treatment market are  Pfizer Inc., F. Hoffmann-La Roche Ltd., AbbVie Inc., Merck And Co Inc., Novartis AG, Bristol Myers Squib company, GlaxoSmithKline PLC, AstraZeneca PLC, Sanofi SA, Eli Lilly And Company, Gilead Sciences Inc., Amgen Inc., Johnson And Johnson Private Limited, Moderna Inc., Regeneron Pharmaceuticals Inc., Hetero labs Ltd., Alexion Pharmaceuticals Inc., Cadila healthcare Ltd., Genentech Inc., Cipla Ltd., Biogen Inc., Vir Biotechnology Inc., Swedish Orphan Biovitrum AB, Dynavax Technologies Corporation, ViiV Healthcare Limited, Panacea Biotec Limited, CureVac N.V., CN Bio Innovations Ltd., Inovio Pharmaceuticals Inc., Chimerix Inc.

The severe acute respiratory-syndrome treatment market report table of contents includes:

1. Executive Summary

2. Severe Acute Respiratory-Syndrome Treatment Market Characteristics

3. Severe Acute Respiratory-Syndrome Treatment Market Trends And Strategies

4. Severe Acute Respiratory-Syndrome Treatment Market – Macro Economic Scenario

…

32. Global Severe Acute Respiratory-Syndrome Treatment Market Competitive Benchmarking

33. Global Severe Acute Respiratory-Syndrome Treatment Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Severe Acute Respiratory-Syndrome Treatment Market

35. Severe Acute Respiratory-Syndrome Treatment Market Future Outlook and Potential Analysis

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model